Difference between revisions of "Oxaliplatin (Eloxatin)"
Line 14: | Line 14: | ||
*[[Pancreatic cancer]] | *[[Pancreatic cancer]] | ||
*[[Rectal cancer]] | *[[Rectal cancer]] | ||
+ | *[[T-cell lymphoma]] | ||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
Revision as of 02:19, 21 June 2013
General information
Class/mechanism: Platinum analog, alkylating-like, which produces interstrand and intrastrand DNA crosslinks that inhibit DNA replication and transcription, causing non-cell cycle specific cytotoxicity and death.[1][2][3]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Aggressive Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Colon cancer
- Esophageal cancer
- Hepatobiliary cancer
- Pancreatic cancer
- Rectal cancer
- T-cell lymphoma
- Testicular cancer
Patient drug information
- Oxaliplatin (Eloxatin) package insert PDF pages 15-16[1]
- Oxaliplatin (Eloxatin) patient drug information (Chemocare)[4]
- Oxaliplatin (Eloxatin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 8/9/2002: Initial FDA approval